Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of concurrent genomic alterations in epidermal growth factor receptor (EGFR)-mutated lung cancer

1 May 2020

Abstract excerpt

Abstract: Comprehensive characterization of the genomic landscape of epidermal growth factor receptor (EGFR)-mutated lung cancers have identified patterns of secondary mutations beyond the primary oncogenic EGFR mutation. These include concurrent pathogenic alterations affecting p53 (60–65%), RTKs (5–10%), PIK3CA/KRAS (3–23%), Wnt (5–10%), and cell cycle (7–25%) pathways as well as transcription factors such as...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Lung Cancer Treatments and Mutations
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32642201
DOI: 10.21037/jtd.2020.03.78

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of concurrent genomic alterations in epidermal growth factor receptor (EGFR)-mutated lung cancerPMID 32642201Read ↗

Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers.Semantic proximity Read ↗

Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A ReviewSemantic proximity Read ↗

Co-occurring genomic alterations in non-small-cell lung cancer biology and therapySemantic proximity Read ↗

Genomic Insights into Innate Resistance in Early-Stage EGFR-Mutant Non-Small Cell Lung Cancer: A Comprehensive Analysis of Next-Generation Sequencing Data.Semantic proximity Read ↗

A Case of Non-Small Cell Lung Cancer with Mutually Exclusive EGFR and KRAS MutationsSemantic proximity Read ↗

The significance of co-mutations in EGFR-mutated non-small cell lung cancer: Optimizing the efficacy of targeted therapies?Semantic proximity Read ↗

Concomitant Genetic Alterations are Associated with Worse Clinical Outcome in EGFR Mutant NSCLC Patients Treated with Tyrosine Kinase InhibitorsSemantic proximity Read ↗

Co-Occurring Driver Genomic Alterations in Advanced Non-Small-Cell Lung Cancer (NSCLC): A Retrospective AnalysisSemantic proximity Read ↗

Landscape of Concomitant Driver Alterations in Classical EGFR-Mutated Non-Small Cell Lung Cancer.Semantic proximity Read ↗

EGFR G719X + S768I co-mutations in NSCLC: genomic landscape and differential responses to EGFR-TKIs in a large real-world cohort.Semantic proximity Read ↗

Genetic alterations shaping tumor response to anti-EGFR therapies.Semantic proximity Read ↗

Personalized Cancer Medicine: Molecular Diagnostics, Predictive biomarkers, and Drug ResistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.